Q-omics provides the consensus-scored ADRA1A profile across patient tissues and cancer cell-line models. ADRA1A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADRA1A is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, ADRA1A RNA expression shows 14,851 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where ADRA1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADRA1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADRA1A survival associations across molecular data types. ADRA1A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADRA1A RNA expression–survival associations across cancer types. High ADRA1A expression shows unfavorable associations in UVM, BLCA and LUSC, but favorable associations in KIRC, LIHC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ADRA1A RNA expression.
This table summarizes ADRA1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ADRA1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADRA1A shows lower tumor expression in LUAD, COAD, THCA, LIHC, KICH and LUSC. The LUAD box plot shows higher ADRA1A RNA expression in normal versus tumor tissue (log2 FC = −1.423, t-test p < 0.001).
This table shows molecular features associated with ADRA1A in patient tissues and cancer cell lines. In patient samples, ADRA1A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ADRA1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
